Zyprexa

Matt Will, University of Indianapolis.

Lilly still had to fight The pharmaceutical giant offered to pay about $700 million to settle about 8,000 claims against In December, Lilly said stock earnings would be at the high end of its forecast.

Next up was Guidant, which issued a safety warning for its implantable devices.

Such problems put merger plans on life support.

At first, Johnson & Johnson planned to buy Guidant for $25 billion.

"They probably still do want Guidant, but they want to get it for less money,” said Greg Andrews, IBJ.

Another company, Boston Scientific, swooped in and made an offer.

That will be a business story next year.

Last month, the grocery chain Marsh said it was studying "strategic alternatives" after its latest financial report showed a big loss.

Marsh may put itself on the market because it's so hard to compete with bigger chains.

In January, ATA had high hopes of challenging its competition.

Then came job cuts and an end to flights out of Indianapolis, forcing ATA to step down as the dominant carrier at Indy to a very small player in the market.

This month, the government honored ATA for its service to the military.

The military gave Lawrence some good news with new jobs coming from the consolidation of defense...

Read more...